A randomized double-blind trial of intravenous immunoglobulin for pemphigus.

@article{Amagai2009ARD,
  title={A randomized double-blind trial of intravenous immunoglobulin for pemphigus.},
  author={Masayuki Amagai and Shigaku Ikeda and Hiroshi Shimizu and Hajime Iizuka and Katsumi Hanada and Setsuya Aiba and Fumio Kaneko and Seiichi Izaki and K. Shimoji T. Kurokawa T. Tamaki and Zenro Ikezawa and Masahiro Takigawa and Mariko Seishima and Toshihiro Tanaka and Yoshiki Miyachi and Ichiro Katayama and Yuji Horiguchi and Sachiko T Miyagawa and Fukumi Furukawa and K Iwatsuki and Kazumasa Iwamoto and Yoshiki Tokura and Masutaka Furue and Takashi Hashimoto and Hironobu Ihn and Sakuhei Fujiwara and Takeji Nishikawa and Hideoki Ogawa and Yasuo Kitajima and Koji Hashimoto},
  journal={Journal of the American Academy of Dermatology},
  year={2009},
  volume={60 4},
  pages={595-603}
}
BACKGROUND Pemphigus is a rare life-threatening intractable autoimmune blistering disease caused by IgG autoantibodies to desmogleins. It has been difficult to conduct a double-blind clinical study for pemphigus partly because, in a placebo group, appropriate treatment often must be provided when the disease flares. OBJECTIVE A multicenter, randomized, placebo-controlled, double-blind trial was conducted to investigate the therapeutic effect of a single cycle of high-dose intravenous… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…